µ-Opioid receptor agonists are commonly used to treat pain despite their adverse effects. In preclinical studies, cannabinoid receptor agonists increase the potency of opioids for producing antinociceptive but not reinforcing effects. It is unknown whether other adverse effects of these drugs, such as impairment of complex behavior, are enhanced by their co-administration. This study characterized the effects of morphine (µ-opioid receptor agonist; 0.32-5.6 mg/kg, subcutaneously) and CP55940 (CB 1 /CB 2 cannabinoid receptor agonist; 0.0032-0.32 mg/ kg, subcutaneously), alone and in mixtures, in monkeys (n = 3) choosing between one pellet delivered immediately and two pellets delivered after a delay. Two consecutive choices of the immediate or delayed reward decreased or increased, respectively, the delay. The median adjusted delay, indicating indifference between the immediate and delayed reinforcers, was increased by morphine (3.2 mg/kg) and CP55940 (0.01-0.032 mg/kg). Performance after administration of morphine (0.32 and 1 mg/kg)/CP55940 (0.0032-0.032 mg/kg) mixtures was not different from performance after CP55940 alone. Neither morphine, CP55940, nor mixtures decreased the median adjusted delay (i.e. increased impulsivity). These findings failed to confirm previous studies showing that morphine increases impulsivity, perhaps because of procedural differences among studies. Treatment of pain often requires repeated drug administration; thus, it remains to be determined whether the present findings predict the effects of chronically administered morphine/CP5540 mixtures on impulsive choice.
Introduction µ-Opioid receptor agonists are commonly prescribed to treat moderate to severe pain, despite their welldocumented adverse effects (e.g. constipation, abuse). One strategy for reducing the likelihood of adverse effects of opioids is to combine them with drugs that produce the desired therapeutic effect through nonopioid mechanisms. In a mixture, smaller doses of each drug might achieve the desired therapeutic effect while also avoiding the adverse effects that occur with larger doses of either drug administered alone (Smith, 2008) . In preclinical studies, small doses of a µ-opioid receptor agonist combined with a cannabinoid receptor agonist have antinociceptive effects that are comparable to those produced by much larger doses of the opioid alone; the interaction between µ-opioid receptor agonists and cannabinoid receptor agonists is supra-additive (synergistic) for antinociceptive effects in mice (Cichewicz and McCarthy, 2003; Tham et al., 2005; Kazantzis et al., 2016) .
Both opioids and cannabinoids are widely abused (Volkow et al., 2014; Panlilio et al. 2015) and previous studies evaluated whether abuse-related effects of these drugs were similarly enhanced in mixtures (Li et al., 2008; Maguire and France, 2014) . The cannabinoid receptor agonists Δ 9 -tetrahydrocannabinol (THC) and CP55940 did not enhance the positive reinforcing effects of heroin (µ-opioid) and CP55940 attenuated the discriminative stimulus effects of morphine in rhesus monkeys discriminating morphine from saline Maguire et al., 2013; France, 2016a, 2016b) . Smaller doses of each drug in mixtures achieved the desired antinociceptive effect without enhancing an abuserelated effect, supporting the notion that opioid/cannabinoid mixtures might be useful for treating pain without the risk of abuse that currently limits the therapeutic use of µ-opioids. It is unknown whether other adverse effects of opioids and cannabinoids are enhanced by their coadministration.
The tendency to prefer smaller immediate over larger delayed reinforcers reflects a form of impulsivity, termed delay discounting, which is thought to be associated with drug abuse (Perry and Carroll, 2008; Odum, 2011; Bickel et al., 2014) . Humans who are dependent on an opioid discount delayed monetary reinforcers more rapidly than nonusers (Madden et al., 1997; Kirby and Petry, 2004) . In rats, the µ-opioid receptor agonist morphine increases choice for a small amount of food delivered immediately and concomitantly decreases choice for a large amount of food delivered after a delay (Pitts and McKinney, 2005; Pattij et al., 2009) . Enhanced delay discounting of nondrug reinforcers might represent a general predisposition to prefer immediately available reinforcers rather than larger delayed reinforcers, thereby increasing an individual's vulnerability for drug abuse. This view is supported by studies in rats showing that steeper discounting of food reinforcers predicted cocaine self-administration and reinstatement of previously extinguished responding in the presence of a cocaine-paired stimulus (Perry et al., 2005; Anker et al., 2009 ). Another possibility is that enhanced discounting might be a result of drug use. Acute administration of morphine can decrease preference for delayed versus immediate food reinforcers (i.e. increased discounting) in pigeons (Eppolito et al., 2013) , rats (Kieres et al., 2004; Harvey-Lewis and Franklin, 2015) , and rhesus monkeys (Maguire et al., 2016) , and repeated administration of an opioid can increase delay discounting as well as other forms of impulsivity, such as response inhibition (Verdejo-García et al., 2007; Harvey-Lewis et al., 2012) .
Compared with opioids, much less is known about the effects of cannabinoids on delay discounting, and the findings reported to date have varied among studies. For example, THC can decrease or increase impulsive choice (Wiskerke et al., 2011; Tanno et al., 2014) in rats choosing between smaller immediate and larger delayed food reinforcers. In humans, THC significantly enhanced motor impulsivity (i.e. a failure to inhibit responding; Metrik et al. 2012) . Nonetheless, opioids and cannabinoids can affect attention, inhibition, and decision-making as reflected by impairments in various behavioral tasks (McDonald et al., 2003; Ramaekers et al., 2006; Friswell et al., 2008; Crean et al., 2011; Dhingra et al., 2015; Irimia et al., 2015) ; however, the effects of opioid/cannabinoid mixtures on complex behavior have not been investigated thoroughly. Given the hypothesized relationship between delay discounting and drug abuse, it is important to assess for potential adverse effects of opioid/cannabinoid mixtures on delay discounting performance and whether the effects of mixtures might be greater than either drug administered alone.
Enhanced impulsivity by opioids and cannabinoids in combination would limit the therapeutic potential of these mixtures. The present study characterized the effects of the µ-opioid receptor agonist morphine, the CB 1 /CB 2 cannabinoid receptor agonist CP55940, and morphine/ CP55940 mixtures in rhesus monkeys responding under an impulsive choice task. In addition, this study assessed the feasibility of using an adjusting delay procedure (Mazur, 1988) to study behavioral and pharmacological interventions in monkeys.
Methods

Subjects
Male rhesus monkeys (Macaca mulatta) were 7.1, 8.9, and 9.1 years old at the start of the experiment and weighed 8.5-10.0 kg. The monkeys were housed individually under a 14/10-h light/dark cycle. Monkeys had unrestricted access to water while in their home cages and were fed primate chow (High Protein Monkey Diet; Harlan Teklad, Madison, Wisconsin, USA), fresh fruit, and peanuts daily after experimental sessions. The monkeys were maintained at a healthy body weight by food received in sessions and in the home cage. Monkeys were previously trained to press levers for food pellets and had received drug injections (Maguire et al., 2016) . The monkeys had not received any drug for at least 2 months prior to the current study. The experimental protocol was approved by the Institutional Animal Care and Use Committee at the University of Texas Health Science Center at San Antonio, Texas, USA and was carried out in accordance with guidelines set forth by the Guide for the Care and Use of Laboratory Animals.
Apparatus
Sessions were conducted in ventilated, sound-attenuating operant-conditioning chambers while monkeys were seated in commercially available primate chairs (Model R001; Primate Products, Miami, Florida, USA). The chambers contained a custom-made response panel with two retractable response levers (Model ENV-612M; Med Associates, St Albans, Vermont, USA), a pellet receptacle, and three stimulus lights horizontally aligned 15.5 cm apart (center-to-center). Monkeys were seated approximately eye level with the stimulus lights, which could be transilluminated red, green (left and right lights), or white (center light). The response levers were positioned 14 cm below the left and right stimulus lights. A food hopper (Model ENV-203; Med Associates) dispensed 300-mg raspberry-flavored sucrose pellets (5-TUT; TestDiet, Richmond, Indiana, USA) to a receptacle centrally located between the two levers. Med-PC IV software and a PCcompatible interface (Med Associates) controlled stimulus events and recorded data.
Procedure
General procedure
Sessions comprised up to 15 blocks of four trials (i.e. a maximum of 60 trials). The first two trials of each block were forced trials in which either the left lever and light or the right lever and light were presented. The lever position (i.e. left or right) was selected at random for the first forced trial and the alternative lever was presented in the second forced trial. Completing 30 responses on the lever (fixed ratio 30) retracted the lever, extinguished the stimulus light, and delivered a reinforcer. For immediately delivered reinforcers, the food hopper dispensed a pellet (or pellets) while the center light was illuminated white for 0.2 s. For delayed reinforcers, the center white light remained illuminated for the length of the delay until the pellets were dispensed. Each food delivery was followed by a 30-s timeout, during which the lights were extinguished. The timeout between lever retraction and presentation of the next trial was held constant in each block; after an immediate reinforcer was delivered, the length of the timeout was 30 s plus the length of the delay for the alternative reinforcer in that block. When both reinforcers were delivered immediately, the timeout was 30 s.
The next two trials of each block were choice trials in which the contingencies were identical to the previous two forced trials, except that both the left and right levers and lights were presented concurrently. Monkeys could respond on either lever; 30 consecutive responses on a lever delivered the corresponding reinforcer. If a monkey chose the delayed reinforcer in both choice trials, then the delay increased by 25% in the next block. Conversely, if a monkey chose the immediate reinforcer in both choice trials, then the delay decreased by 25% in the next block. If a monkey chose one of each reinforcer in the two choice trials of a block, the delay remained the same in the subsequent block. Sessions ended after 15 blocks or 100 min, whichever occurred first.
Environmental manipulations
Before testing drugs, several environmental manipulations were conducted to assess the sensitivity of this procedure to the experimental contingencies (i.e. reinforcer amounts and delay). The stimulus color and lever position (i.e. green/left and red/right; or red/left and green/right) always remained constant for a block of four trials, with the order being pseudorandomized each session so that the same color/lever configuration did not occur in more than three consecutive blocks or in more than eight blocks total. Therefore, to assess whether there was a bias toward a stimulus light on the basis of its color, rather than the consequences that it signals, the reinforcers associated with the red and green stimulus lights were reversed twice. Initially, a green stimulus light above a lever signaled one pellet delivered immediately and a red stimulus light three pellets delivered immediately. Once the monkeys chose three pellets over one pellet (≥80% choice for at least two consecutive sessions), the stimulus conditions were reversed such that the green stimulus and the red stimulus signaled three pellets and one pellet, respectively. The stimulus conditions were reversed once more, restoring the initial conditions with green signaling one pellet and red signaling three pellets. For the remainder of this study, the green stimulus signaled a smaller number of pellets relative to the amount signaled by the red stimulus.
To explore whether the difference between reinforcer amounts impacted performance (adjusted delay), the number of pellets for the larger and smaller reinforcers were manipulated in the following three conditions: three pellets versus one pellet, two pellets versus one pellet, and three pellets versus two pellets. These pellet amounts were chosen because the relative differences of 3-, 2-, and 1.5-fold could be compared with the absolute differences of 2, 1, and 1, respectively. The conditions were tested when both reinforcers were delivered immediately as well as when the larger amount was delayed (according to the adjusting delay procedure described above). The first time a delay was introduced in a given condition, the delay was set to 10 s for the first block. Thereafter, the delay for the first block was set to the median adjusted delay from the preceding session. Performance was considered stable when the following criteria were satisfied: (i) the median adjusted delay for three consecutive sessions was within 20% of the average of those three sessions; (ii) the median adjusted delay was neither increasing nor decreasing across three consecutive sessions; and (iii) the adjusted delay in the last three blocks of the third consecutive session was neither increasing nor decreasing.
To test whether responding alternated on both levers independent of delay, the delay for the first block of the session was set to 100 s for three consecutive sessions. This test was performed in the three versus two pellet condition for two subjects (monkeys AN and GE) and in the three versus one pellet condition for the other subject (monkey BR). If monkeys simply alternated responding across levers at random, then the delay would not be expected to increase or decrease significantly, with the median adjusted delay remaining close to 100 s. Conversely, if the median adjusted delay was sensitive to delay, then the pattern of responding would decrease the adjusted delay, eventually approximating the median adjusted delay from the three versus two pellet condition for monkeys AN and GE and the three versus one pellet condition for monkey BR. The order of the environmental manipulations and the number of sessions in each condition varied for each monkey, except that two pellets versus one pellet (with delays) was always implemented last.
Dose-effect determinations: morphine, CP55940, and morphine/CP55940 mixtures
The condition in which drugs were tested for all monkeys was two pellets versus one pellet. Monkeys received saline injections (0.3 ml) 15 min before every session, except when morphine was tested. At least three consecutive saline sessions preceded each drug test and performance was considered stable when the median adjusted delay was within 20% of the average of those three sessions and neither increasing nor decreasing across consecutive sessions. In addition, if three sequential increases or decreases to the delay occurred in the last three blocks, then performance did not satisfy the stability criteria for drug testing. For any session that immediately followed a drug test, the delay for the first block was set to the median adjusted delay from the most recent saline session. Dose-response functions were determined twice for morphine alone then twice for CP55940 alone. Doses were tested in an irregular order until the dose-response function ranged from at least one ineffective dose (within 20% of saline control values both for median adjusted delay and for response rate) and up to a dose that decreased responding to less than or equal to 20% of control values. Doses were increased or decreased by 1/2-log units, except from 3.2 to 5.6 mg/kg morphine. For monkey GE, 0.32 mg/kg morphine was tested after the dose-response function for CP55940 was completed.
The major aim of this study was to assess the potential interaction between morphine and CP55940 in the delay discounting task. The doses of morphine chosen for mixtures were 0.32 and 1.0 mg/kg because, administered alone, they were the largest doses that did not decrease the control response rates by more than 20%.
Drugs
Morphine sulfate was provided by the National Institute on Drug Abuse Drug Supply Program (Bethesda, Maryland, USA) and was dissolved in sterile water. 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-methyloctan-2-yl)phenol (CP55940; Sigma-Aldrich, St. Louis, Missouri, USA) was dissolved in pure ethanol (2 ml ethanol/bottle containing 10 mg CP55940) and then diluted with a solution of 1 : 1 : 18 ethanol : emulphor : saline. Drugs were administered subcutaneously in a volume of 0.2-0.8 ml. Pretreatment times were 15 min for morphine and 60 min for CP55940; behavioral effects of morphine and CP55940 are apparent within 15 and 60 min, respectively, and last at least 90 min in various operant-conditioning tasks, including delay discounting (Maguire et al., 2012 (Maguire et al., , 2013 (Maguire et al., , 2016 . All doses were expressed as the weight of the forms noted above.
Data analyses
When both reinforcers were delivered immediately (no delay), the primary measure was the proportion choice for the larger reinforcer [the number of choices for the larger reinforcer divided by the total number of choice trials completed (i.e. maximum 30 choice trials)]. For sessions in which delay adjusted for the larger reinforcer, there were two primary measures: the median adjusted delay (based on up to 15 delays/session) and the overall response rate (total number of responses divided by the total duration the levers were extended).
To compare the median adjusted delays in each of the pellet conditions (three versus one, two versus one, and three versus two), the first three sessions that satisfied the stability criterion were examined. Because monkey GE did not fulfill stability criteria in the three versus one pellet condition (the median adjusted delay was still increasing even by session 10), the last three sessions were examined. A one-way repeated measures analysis of variance (ANOVA) with Bonferroni's post-hoc test was conducted for each monkey and then again for each condition to compare among subjects.
To analyze the effects of morphine and CP55940 administered alone, the mean and 95% confidence interval (CI) from each dose were compared with the mean and 95% CI from control (saline) sessions; if the 95% CIs did not overlap, the effects were considered significant. Because the potency of CP55940 varied among subjects, the dose producing the largest increase in the median adjusted delay was determined for each monkey (i.e. E max ), with smaller and larger doses expressed in log-unit doses relative to the E max (Manvich et al., 2012) . A two-way repeated-measures ANOVA was used to analyze the effects of morphine/ CP55940 mixtures on the ascending limb of the dose-response curve for median adjusted delay. To analyze the effects of morphine/CP55940 mixtures on response rate, the data were converted into a percentage of the control (vehicle) response rate. ED 50 values were obtained for individual monkeys by fitting a linear regression to the data between 20 and 80% (including not more than one dose producing less than 20% effect and not more than one dose producing more than 80% effect). Potency ratios for each subject were calculated by dividing the ED 50 of CP55940 by the ED 50 of CP55940 with morphine. Data were then averaged among the three subjects; when the 95% CI did not contain one, the shift was considered significant. Analyses were conducted using GraphPad Prism (GraphPad Software Inc., La Jolla, California, USA).
Results
With no delay, monkeys chose the larger amount of pellets over the smaller amount (Fig. 1) and completed all trials (not shown). The number of sessions needed to satisfy the criteria (≥0.8 proportion choice for the larger amount) when three pellets were signaled by the red stimulus and one pellet was signaled by the green stimulus was one session for monkeys BR and GE and two sessions for monkey AN. When the stimuli signaling each reinforcer were reversed, monkeys AN and GE satisfied criteria in two sessions and monkey BR in four sessions. When the stimuli were reversed again, monkeys BR and GE required four and five sessions, respectively, to satisfy criteria, whereas monkey AN satisfied criteria in one session. Finally, when the number of pellets for the smaller reinforcer was increased from one pellet to two pellets and when the number of pellets for the larger reinforcer was decreased from three pellets to two pellets, monkeys chose the larger amount and satisfied criteria within two sessions.
When the relative difference between the larger and smaller number of pellets was decreased, the adjusted delays were shorter (Fig. 2) . The difference in the adjusted delay between conditions was statistically significant for monkey AN (F 2,8 = 996.2, P < 0.01; t = 35.0, P < 0.05 for three vs. one pellets and two vs. one pellets; t = 41.5, P < 0.05 for three vs. one pellets and three vs. two pellets; t = 6.5, P < 0.05 for two vs. one pellets and three vs. two pellets) and for monkey BR (F 2,8 = 58.6, P < 0.01; t = 5.4, P < 0.05 for three vs. one pellets and two vs. one pellets; t = 10.8, P < 0.05 for three vs. one pellets and three vs. two pellets; t = 5.5, P < 0.05 for two vs. one pellets and three vs. two pellets). For monkey GE, the difference was significant only for three versus one pellets compared with three versus two pellets (F 2,8 = 11.6, P < 0.02; t = 4.81, P < 0.05).
In the three versus one pellet condition, the adjusted delay for monkey BR was significantly shorter than the adjusted delay for monkey GE (F 2,8 = 9.1, P = 0.03; t = 4.3, P < 0.05), but not monkey AN; monkey AN was not significantly different from monkey GE. In the two versus one pellet condition and the three versus two pellet condition, monkey GE had significantly longer adjusted delays than monkey AN (F 2,8 = 34.7, P < 0.01; t = 7.3, P < 0.05 for two vs. one pellets; F 2,8 = 56.1, P < 0.01; t = 9.3, P < 0.05 for three vs. two pellets) and monkey BR (t = 7.2, P < 0.05 for two vs. one pellets; t = 9.1, P < 0.05 for three vs. two pellets), but monkeys AN and BR did not differ significantly.
When the initial delay of a session was 100 s, the monkeys adjusted the delay downward to values that approximated the median adjusted delay for each monkey (right panels, Fig. 2 ). The median adjusted delay in three representative sessions of the three versus two pellet condition was 9.9, 10.0, and 10.0 for monkey AN and 34.0, 26.3, and 32.8 s for monkey GE; these monkeys adjusted the delay to a minimum 12.5 s (monkey AN) and 24.4 s (monkey GE) when the initial delay was 100 s for three sessions. The median adjusted delay was 33.0, 33.9, and 31.9 s for monkey BR in the three versus one pellet condition and the delay was adjusted downward to a minimum of 22.2 s when the initial delay was 100 s.
Morphine increased the median adjusted delay in all monkeys (Fig. 3) . The increase was significant in monkey AN at 1.0, 3.2, and 5.6 mg/kg, in monkey BR at 5.6 mg/kg, and in monkey GE at 1.0 mg/kg. Morphine significantly decreased response rates at 3.2 and 5.6 mg/kg in all monkeys, and also at 1.0 mg/kg in monkey AN. At least one dose of CP55940 increased the median adjusted delay in each monkey (upper panels, Fig. 4) . Compared with the control values (three saline sessions before each CP55940 test; see means and 95% CIs in Table 1 ), the increase was significant in monkey AN at 0.01 and 0.032 mg/kg, in monkey BR at 0.032 mg/kg, and in monkey GE at 0.01 mg/kg. CP55940 dose-dependently decreased responding in all monkeys (middle panels, Fig. 4 ). The rate-decreasing effect of CP55940 was significant at 0.1 mg/kg for all monkeys and at 0.32 mg/kg for monkey BR (compared with the mean control response rates and 95% CIs; Table 1 ). The number of choice trials completed (lower panels, Fig. 4 ) tended to co-vary inversely with the median adjusted delay but did not necessarily co-vary with response rate.
The potency of CP55940 differed among individual monkeys (i.e. an E max of 0.01 mg/kg for monkeys AN and GE and 0.032 mg/kg for monkey BR); therefore, the median adjusted delay and response rate were plotted as a function of the log-unit dose relative to the E max (Fig. 4) . CP55940 increased the group median adjusted delay 1.9-fold from 59.9 s (mean for vehicle) to 109.5 s (mean for E max ). A two-way repeated measures ANOVA showed a significant main effect of CP55940 (F 2,12 = 6.68, P = 0.01) but not morphine (F 2,6 = 0.06, NS), and there was no significant interaction between CP55940 and morphine (F 4,12 = 1.65, NS). The dose of CP55940 that significantly increased the median adjusted delay was without effect on response rate. For all monkeys, the CP5540 dose-response curve for response rate shifted leftward when CP55940 was administered in combination with either 0.32 or 1.0 mg/kg morphine, with a significant increase in the potency of CP55940 to decrease responding (Table 2) . Discussion µ-Opioid receptor agonists are commonly used to treat moderate to severe pain; however, opioids are also the most widely abused of all prescription medications with fatal overdoses having reached epidemic levels (Volkow et al., 2014; Centers for Disease Control and Prevention CDC, 2016) . Consequently, there is a need to identify pharmacological treatments for pain with fewer adverse effects than those currently limiting the use of µ-opioid receptor agonists. Previous studies showed that cannabinoid receptor agonists Proportion choice for the larger number of pellets (vertical axes; from a maximum of 30 choice trials) for sessions (horizontal axes) in which the larger and the smaller number of pellets were delivered immediately (i.e. no delay). Each symbol denotes an individual subject. The color of the stimulus light signaling the availability of the larger amount is indicated for each condition.
increase the potency of opioids for producing antinociceptive but not reinforcing effects (Maguire et al., 2013) . Abuse of µ-opioid receptor agonists is associated with enhanced impulsivity (delay discounting) in humans, and experimenteradministered opioids can enhance delay discounting in nonhumans (Kirby and Petry, 2004; Pitts and McKinney, 2005) . Therefore, this study evaluated the effects of the µ-opioid receptor agonist morphine and the CB 1 /CB 2 receptor agonist CP55940, alone and in mixtures, on delay discounting performance in rhesus monkeys to determine whether the effects of mixtures are greater than either drug administered alone. The results showed that neither morphine nor CP55940 alone enhanced delay discounting, and at least some doses decreased delay discounting (increased the median adjusted delay) in every monkey. Co-administration of morphine (0.32 and 1.0 mg/kg) and CP55940 in mixtures also decreased discounting, with the effects on median adjusted delay not being significantly different from the effects of either drug administered alone (i.e. no interaction). Morphine significantly increased the potency of CP55940 to decrease response rates, even though 0.32 and 1.0 mg/kg morphine did not decrease response rates by more than 20% when administered alone.
The design of the delay discounting procedure used in the present study was based on the adjusting delay procedure described by Mazur (1988 Mazur ( , 1997 and Cardinal et al. (2002) . Stable performance in this task occurs when a The adjusted delay (vertical axes) for each block (horizontal axes) in three representative sessions from the three versus one pellet, two versus one pellet, and three versus two pellet conditions; the three sessions shown for each condition were consecutive and satisfied the criteria for stability (see text for details). The horizontal solid lines through the open symbols represent the median delay for each session. Filled symbols represent the adjusted delay when the initial delay for the session was 100 s. Dashed horizontal lines through the filled symbols are the means for the adjusted delay (the median adjusted delay average for three sessions) in the three versus two pellet condition (monkeys AN and GE) or the two versus one pellet condition (monkey BR). Each symbol denotes an individual subject (same symbols as in Fig. 1 ).
Morphine/CP55940 mixtures Minervini and France 65 subject allocates responding approximately equally between the immediate and delayed reinforcers. The adjusted delay represents the point at which a subject is indifferent between a smaller immediate reinforcer and a larger delayed reinforcer. For each monkey in this study, there was a delay at which they were indifferent between a smaller immediate and a larger delayed reinforcer, regardless of baseline delay. However, there were differences among monkeys; for example, under control conditions, monkey GE had significantly longer baseline delays compared with monkeys AN and BR. Monkey GE also showed greater variability in the adjusted delay under control and drug conditions. Because the delay increased or decreased by 25% depending on performance, the absolute values of the adjustments for monkey GE were larger than the adjustments for other monkeys. Cardinal et al. (2002) reported that larger adjustments can produce greater variability, and Mazur (1988) noted that larger adjustments might lead to relatively larger stable delays. Monkey GE also had much lower response rates compared with the other two monkeys, possibly related to the longer delays. In pigeons and rats, with longer delays, the latency to respond increases and response rate decreases (Green et al. 1981; Green and Estle 2003) . Notwithstanding the differences among monkeys under control conditions, the same pattern of performance occurred (increased delay) when morphine and CP55940 were administered; thus, drug effects did not appear to depend on baseline performance.
Previous studies reported enhanced discounting following the administration of an opioid receptor agonist (Harvey-Lewis and Franklin, 2015; Maguire et al., 2016), Morphine dose-response curves for median adjusted delay (s; upper panels), response rate (responses/s; middle panels), and choice trials completed (lower panels) for individual subjects. Each data point represents the mean of two determinations and error bars denote 95% confidence interval (CI). The horizontal shaded bars represent the 95% CI from control sessions (three consecutive saline sessions preceding each drug test). See text for statistical analyses.
suggesting that a potential adverse effect of opioids is increased impulsivity. In this study, neither morphine nor CP55940 increased impulsivity, which would be reflected by a decrease in the median adjusted delay. Conversely, both morphine and CP55940, administered alone, increased the median adjusted delay (i.e. decreased impulsivity). This finding cannot easily be attributed to or interpreted as a lever-position bias or Dose-response curves for CP55940 administered alone and in combination with morphine (0.32 and 1.0 mg/kg) for median adjusted delay, response rate, and choice trials completed for individual subjects. In the rightmost panels, data for the median adjusted delay, response rate (percentage of the control), and choice trials (percentage of the control) are averaged for the three subjects and plotted as a function of the log-unit dose relative to the E max dose for CP55940 alone. Each data point, including symbols above 'V' (CP55940 vehicle), represents the mean of two determinations and error bars denote 1 SEM. See text and Table 2 for details on statistical analyses. The median adjusted delay was not calculated if a monkey completed fewer than eight trials (i.e. at least two blocks had to be completed, allowing for the opportunity to adjust the delay). CI, confidence interval. The potency ratio (CP55940/CP55940 + morphine) is shown for individual monkeys and for the group mean with 95% confidence intervals. CI, confidence interval.
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perseverative responding because the lever position associated with the delayed reinforcer alternated within session. Previous studies used a different procedure in which the delay to the larger reinforcer increased by a fixed duration within session and the lever position associated with each reinforcer remained constant (Evenden and Ryan, 1996) . Previous studies also used the same discriminative stimuli for the immediate and delayed reinforcer, whereas the present study used distinct stimuli (i.e. green stimulus for the immediate reinforcer and red stimulus for the delayed reinforcer). Although it is possible that increases in the median adjusted delay result from a stimulus (color) bias, this is unlikely because the monkeys were trained to discriminate between larger and smaller reinforcer amounts when the stimulus colors were reversed. Thus, procedural differences between the present study and previous studies might account for the different effects of morphine on impulsivity. The adjusting delay procedure might be sensitive to different aspects of impulsivity compared with procedures using fixed, ascending, or descending delays (Maguire et al., 2016; Tanno et al., 2014) , much in the same way that delay discounting is sensitive to different aspects of impulsivity compared with motor (impulsivity) tasks. There is no a priori reason to expect that different procedures will necessarily measure the same features of something as complex and multifaceted as impulsivity. The current findings underscore the importance of testing the generality of drug effects on different aspects of impulsivity.
Statistical analyses (ANOVA) indicated a significant effect of CP55940 but not morphine on delay discounting, and there was no significant interaction between morphine and CP55940. Morphine/CP55940 mixtures did not increase impulsivity (i.e. decrease median adjusted delay) in this task. Rather, morphine/CP55940 mixtures increased the median adjusted delay, which might reflect less impulsivity. This interpretation is consistent with previous studies showing that cannabinoids selectively enhance some (antinociceptive) but not other (positive reinforcing) effects of opioids (Maguire and France, 2016a) and attenuate the discriminative stimulus effects of opioids (Maguire and France, 2016b) . There are at least three other possible explanations for these drug-induced increases in the median adjusted delay. First, cannabinoids have well-known hyperphagic effects (Berry and Mechoulam, 2002) , which might have increased preference for the larger (sometimes delayed) amount of food; however, it is worth noting that the effects of drugs under free-feeding conditions often are not predictive of effects on operant behavior maintained by food reinforcement (LeSage et al., 2004) . Second, cannabinoids can alter time perception, which is an important feature in delay discounting (Wittmann and Paulus, 2008) ; however, this interpretation is not consistent with findings in humans showing that THC caused relatively short (2-4 s) but not long (8-32 s) intervals to be overestimated. Third, both morphine and CP55940 have sedative effects (Dhingra et al., 2015) , which may have increased other behavior associated with nonprogrammed reinforcement (e.g. sleep) to occur during the delay, in turn making the delay to the programmed food reinforcement more tolerable. This interpretation is consistent with the finding in the present study that rate-decreasing effects were greatest with morphine/CP55940 mixtures.
This study used acute drug administration to examine possible interactions between morphine and CP55940 on complex choice behavior. Particularly relevant to the clinical use of opioids are conditions of chronic drug administration, under which enhanced discounting can occur (Setlow et al., 2009; Zancy and de Wit, 2009) ; the potential for morphine/CP55940 mixtures to adversely affect complex operant behavior (e.g. impulsive choice) has yet to be examined under chronic administration conditions. Opioid abuse and opioid dependence are associated with increased delay discounting and probability discounting in humans (Madden et al., 1997; Kirby et al., 1999; Odum et al., 2000; Kirby and Petry, 2004) , and humans who self-report regular or daily marijuana use have steeper discounting functions than nonusers (Johnson et al., 2010; Aston et al., 2016; Mejía-Cruz et al., 2016) . Thus, compared with acute dosing conditions, the effects of opioid/cannabinoid mixtures might be qualitatively and/or quantitatively different during repeated administration or after discontinuation of repeated treatment.
Conclusion
In this study, the effects of CP55940 and morphine on response rate, but not adjusted delay, in an impulsive choice task, were enhanced by their co-administration in rhesus monkeys. These results extend previous research showing that cannabinoids enhance antinociceptive effects, but not reinforcing or discriminative stimulus effects of opioids and add to a growing body of evidence supporting the therapeutic potential of opioid/cannabinoid mixtures. It is unclear whether the present findings are predictive of the effects of opioid/cannabinoid mixtures on other forms of impulsivity (e.g. motor impulsivity) or during chronic drug treatment, in part because different procedures appear to be sensitive to different measures of impulsivity. Because pain patients often require repeated drug administration, the effects of morphine/CP5540 mixtures on various complex behaviors should be evaluated during and after daily drug administration. The relationship among pain, impulsivity, and opioids appears to be complex; emerging evidence shows that chronic pain increases motor impulsivity and acute administration of the µ-opioid receptor agonist remifentanil further increases motor impulsivity in an additive manner, even at pain-relieving doses (Kurita et al., 2015) . If opioid/cannabinoid mixtures enhance impulsivity, then the therapeutic potential of these drugs likely would be limited.
